Fever as the only manifestation of hypersensitivity reactions associated with oxaliplatin in a patient with colorectal cancer Oxaliplatin-induced hypersensitivity reaction

被引:11
作者
Saif, M. Wasif
Roy, Shailja
Ledbetter, Leslie
Madison, Jennifer
Syrigos, Kostas
机构
[1] Yale Univ, Sch Med, Sect Med Oncol, New Haven, CT 06520 USA
[2] Univ Alabama, Birmingham, AL USA
[3] Sotiria Gen Hosp, Athens Med Sch, Athens, Greece
关键词
oxaliplatin; hypersensitivity reaction; fever; colon cancer;
D O I
10.3748/wjg.v13.i39.5277
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Hypersensitivity reactions (HSR) to oxaliplatin in patients with colorectal cancer include facial flushing, erythema, pruritis, fever, tachycardia, dyspnea, tongue swelling, rash/hives, headache, chills, weakness, vomiting, burning sensations, dizziness, and edema. We report a patient with fever as the sole manifestation of initial HSR, review the literature and discuss the management of HSR. A 57-year-old female with T3N2M0 rectal adenocarcinoma received modified FOLFOX-6. She tolerated the first 8 cycles without any toxicities except grade 1 peripheral neuropathy and nausea. During 9(th) and 10(th) infusions, she developed fever to a maximum of 38.3 degrees C with stable hemodynamic status despite medications. During 11(th) infusion, she developed grade 3 HSR consisting of symptomatic bronchospasm, hypotension, nausea, vomiting, cough, and fever. On examination, she was pale, cyanotic, with a temperature of 38.8 degrees C, BP dropped to 95/43 mm Hg, pulse of 116/min and O-2 saturation of 88%-91%. She was hospitalized for management and recovered in 24 h. Fever alone is not a usual symptom of oxaliplatin HSR. It may be indicative that the patient may develop serious reactions subsequently, as did our patient who developed hypotension with the third challenge. Treatment and prevention consists of slowing the infusion rate, use of steroids and antagonists of Type 1 and 2 histamine receptor antagonists, whereas desensitization could help to provide the small number of patients who experience severe HSR with the ability to further receive an effective therapy for their colorectal cancer. (C) 2007 WJG. All rights reserved.
引用
收藏
页码:5277 / 5281
页数:5
相关论文
共 25 条
[1]   Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer [J].
Andre, T ;
Boni, C ;
Mounedji-Boudiaf, L ;
Navarro, M ;
Tabernero, J ;
Hickish, T ;
Topham, C ;
Zaninelli, M ;
Clingan, P ;
Bridgewater, J ;
Tabah-Fisch, I ;
de Gramont, A .
NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (23) :2343-2351
[2]   Anaphylaxis to cisplatin following nine previous uncomplicated cycles [J].
Basu R. ;
Rajkumar A. ;
Datta N.R. .
International Journal of Clinical Oncology, 2002, 7 (6) :365-367
[3]   Hypersensitivity and idiosyncratic reactions to oxaliplatin [J].
Bhargava, P ;
Gammon, D ;
McCormick, MJ .
CANCER, 2004, 100 (01) :211-212
[4]   Hypersensitivity reactions related to oxaliplatin (OHP) [J].
Brandi, G ;
Pantaleo, MA ;
Galli, C ;
Falcone, A ;
Antonuzzo, A ;
Mordenti, P ;
Di Marco, MC ;
Biasco, G .
BRITISH JOURNAL OF CANCER, 2003, 89 (03) :477-481
[5]  
Cancer Therapy Evaluation Program, 2006, COMM TERM CRIT ADV E
[6]   Skin testing and hypersensitivity reactions to oxaliplatin [J].
Garufi, C ;
Cristaudo, A ;
Vanni, B ;
Bria, E ;
Aschelter, AM ;
Santucci, B ;
Terzoli, E .
ANNALS OF ONCOLOGY, 2003, 14 (03) :497-498
[7]   Randomized controlled trial of reduced-dose bolus fluorouracil plus leucovorin and irinotecan or infused fluorouracil plus leucovorin and oxaliplatin in patients with previously untreated metastatic colorectal cancer: A North American intergroup trial [J].
Goldberg, Richard M. ;
Sargent, Daniel J. ;
Morton, Roscoe F. ;
Fuchs, Charles S. ;
Ramanathan, Ramesh K. ;
Williamson, Stephen K. ;
Findlay, Brian P. ;
Pitot, Henry C. ;
Alberts, Steven .
JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (21) :3347-3353
[8]   Genetic variations in HLA-B region and hypersensitivity reactions to abacavir [J].
Hetherington, S ;
Hughes, AR ;
Mosteller, M ;
Shortino, D ;
Baker, KL ;
Spreen, W ;
Lai, E ;
Davies, K ;
Handley, A ;
Dow, DJ ;
Fling, ME ;
Stocum, M ;
Bowman, C ;
Thurmond, LM ;
Roses, AD .
LANCET, 2002, 359 (9312) :1121-1122
[9]   Hypersensitivity reaction to cisplatin during chemoradiation therapy for gynecologic malignancy [J].
Koren, C ;
Yerushalmi, R ;
Katz, A ;
Malik, H ;
Sulkes, A ;
Fenig, E .
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2002, 25 (06) :625-626
[10]   Hypersensitivity reactions to oxaliplatin: a case report and the success of a continuous infusional desensitization schedule [J].
Lim, KH ;
Huang, MJ ;
Lin, HC ;
Su, YW ;
Chang, YF ;
Lin, J ;
Chang, MC ;
Hsieh, RK .
ANTI-CANCER DRUGS, 2004, 15 (06) :605-607